Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer

Clinical Colorectal Cancer

Volumn 2, Issue 1, 2002, Pages 54-58

  Lersch, Christian ^a   Schmelz, Renate ^a   Eckel, Florian ^a   Erdmann, Johannes ^a   Mayr, Martina ^a   Schulte Frohlinde, Ewert ^a   Quasthoff, Stefan ^b   Grosskreutz, Julian ^b   Adelsberger, Helmuth ^c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

5 Fluorouracacil; Carbamazepine; Chemotherapy; Folinic acid; Neurotoxicity; Oxaliplatin

Indexed keywords

AMIFOSTINE; CARBAMAZEPINE; GABAPENTIN; GLUCONATE CALCIUM; MAGNESIUM CITRATE; MAGNESIUM SULFATE; OXALIPLATIN; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADVANCED CANCER; ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EXPOSURE; HUMAN; IN VITRO STUDY; KINETICS; NEUROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SURAL NERVE; ANIMAL; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; RAT; TOXICITY AND INTOXICATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBAMAZEPINE; COLORECTAL NEOPLASMS; HUMANS; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; RATS; SODIUM CHANNEL BLOCKERS;

EID: 0036018894     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2002.n.011     Document Type: Article

References (33)

1. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: A randomised trial
2. A collective review of the world literature on hepatic cryotherapy
3. Oxaliplatin: A review of its use in the management of metastatic colorectal cancer
4. Oxaliplatin: A review of preclinical and clinical studies
5. Oxaliplatin: Update on an active and safe DACH platinum complex
6. Oxaliplatin in practice
7. Oxaliplatin in colorectal cancer patients living in an arctic or subarctic area: Significant cold-triggered dysesthesias and laryngeal reactions
8. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines
9. Oxaliplatin: Global safety
10. Pharmacokinetics and safety profile of oxaliplatin
11. Central neurotoxicity induced by oxaliplatin: Report on 4 cases
12. Preliminary analysis of possible relationship of oxaliplatin and its biotransformation products to neurotoxicity
13. Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model
14. Neurotoxicity of oxaliplatin (I-OHP) in rats and influence of scheduling
15. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat
16. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model
17. Lack of neurotoxicity of oral bisacetatoamminedichlorocyclohexylamine-platinum(IV) in comparison to cisplatin and tetraplatin in the rat
18. Chemotherapy-induced peripheral neuropathy
19. Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs
20. Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin
21. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels
22. Alteration of sodium channel inactivation kinetics on rat sural nerve by the chemotherapeutic agent oxaliplatin
23. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons
24. The effects of gabapentin on different ligand- and voltage-gated currents in isolated cortical neurons
25. Safety of oxaliplatin in the treatment of colorectal cancer
26. Platinum neurotoxicity: Clinical profiles, experimental models and neuroprotective approaches
27. Acute oxaliplatin neurotoxicity dramatically improved with intravenous calcium and magnesium salts
28. Subcutaneous administration of amifostine: A promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy
29. A new therapeutic option in patients with oxaliplatin-related peripheral neuropathy
30. Randomised trial with or without amifostine to reduce neurotoxic side effects under chemotherapy with oxaliplatin (L-OHP), FA/5-FU
31. Oxaliplatin induced neuropathy: Could gabapentin be the answer?
32. Inhibition of voltage-sensitive sodium channels in neuroblastoma cells and synaptosomes by the anticonvulsant drugs diphenylhydantoin and carbamazepine
33. Prevention of oxaliplatin-induced neuropathy by carbamazepine, a pilot study